One-Month versus Three-Month Formulation of Paliperidone Palmitate Treatment in Psychotic Disorders: Patients’, Relatives’, and Mental Health Professionals’ Perspectives

Overview of attention for article published in Patient preference and adherence, March 2022

Altmetric Badge

Mentioned by

twitter: 1 X user

Citations

dimensions_citation: 5 Dimensions

Readers on

mendeley: 16 Mendeley

Summary X Dimensions citations

So far, Dimensions has found 5 publications that cite this research output.

5

The most recent citing publications are shown below. View all 5 publications that cite this research output on Dimensions.

Cumulative Clinical Experience of the Use of Paliperidone Palmitate 3-Monthly Long-Acting Injection in the Treatment of Schizophrenia: A Critical Appraisal

Article in Drug Healthcare and Patient Safety (September 2023)

Switching from Monthly to Three-Monthly Long-Acting Injectable Paliperidone: A Survey on Subjective Satisfaction and Safety

Article in Patient Preference and Adherence (July 2023)

Tolerability profile of paliperidone palmitate formulations: A pharmacovigilance analysis of the EUDRAVigilance database

Article in Frontiers in Psychiatry (April 2023)